ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the
expression or activation of epidermal growth factor receptor and ERBB2 are altered in many …

The increased target specificity of epidermal growth factor receptor (EGFR) inhibitors
(EGFRIs) is associated with the reduction or abolition of nonspecific and haematopoietic …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

The last few years, new therapies targeting the epidermal growth factor receptor (EGFR)
have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies …

In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer
treatment and numerous are under investigation. These drugs are rationally designed to …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB
receptor family that is abnormally activated in many epithelial tumors. The aberrant …

Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective …

Cancers are heterogeneous tissues comprised of multiple components, including tumor
cells and microenvironment cells. The tumor microenvironment has a critical role in tumor …

Purpose Vascular endothelial growth factor (VEGF) is a potent molecule that mediates tumor
angiogenesis primarily through VEGF receptor 2 (VEGFR2). Bevacizumab, a recombinant …

Purpose To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib
500 mg/day monotherapy in patients with previously treated, advanced breast cancer …